Saving changes...

Done

Error

Oncology Pharmacy Consults Immunotherapy for Metastatic Renal Cell Carcinoma: Novel Treatment Strategies

Oncology Pharmacy Consults Immunotherapy for Metastatic Renal Cell Carcinoma: Novel Treatment Strategies

Oncology Pharmacy Consults Immunotherapy for Metastatic Renal Cell Carcinoma: Novel Treatment Strategies

R. Donald  Harvey, PharmD, FCCP, BCOP
R. Donald Harvey, PharmD, FCCP, BCOP
on behalf of Postgraduate Healthcare Education, LLC

FREE
FREE
FREE

FREE
FREE
FREE

null FREE
FREE
FREE
null FREE
FREE
FREE
Normal Price: FREE FREE

Review:

Launch date: 13 Mar 2017
Expiry Date:

Last updated: 15 Mar 2017

Reference: 172105

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

Management of patients with metastatic renal cell carcinoma (mRCC) continues to evolve. Treatment with interleukin-2 (IL-2) and interferon (INF-α), or a combination of the 2, were standards of care in the early 2000s. Targeted therapies emerged based on an understanding of the mechanisms involved in the pathogenesis of RCC showing improved progression-free survival (PFS), and partial response over interferon-α, with better tolerability. These therapies focused on inhibiting vascular endothelial growth factor and the mammalian target of rapamycin (mTOR). Although targeted therapies have demonstrated PFS benefit, most patients with mRCC eventually relapse, emphasizing the need for treatment options with novel mechanisms of action that could result in improved efficacy and a survival advantage. Understanding of specific host-tumor immune interactions has led to the development of novel antibodies directed against immune checkpoint proteins. Recently, an immune checkpoint inhibitor has shown superiority over an mTOR inhibitor in a selected patient population with disease progression on antiangiogenic therapy. As new therapies are approved, it is important for pharmacists to understand mechanisms of action and roles in the clinic, especially for patients who have received prior therapies, to make informed treatment choices to improve patient outcomes. This enduring case-based activity will provide participants with up-to-date information regarding consulting with patients on prescribing and managing therapies for patients with mRCC.

Objectives

Objectives
At the conclusion of this activity, the participant should be able to:

-Identify recently approved and investigational immunotherapy treatment options for mRCC.
-Recognize unique efficacy and safety considerations regarding the use of immunotherapy in mRCC.
-Assess individual treatment plans incorporating immunotherapy in mRCC.
-Describe key areas of pharmacist interventions in the management of mRCC.
R. Donald  Harvey, PharmD, FCCP, BCOP

Author Information Play Video Bio

R. Donald Harvey, PharmD, FCCP, BCOP
on behalf of Postgraduate Healthcare Education, LLC

R. Donald Harvey, PharmD, FCCP, BCOP Associate Professor, Hematology/Medical Oncology Director, Phase 1 Clinical Trials Section Winship Cancer Institute of Emory University Atlanta, Georgia

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.00 Hours -
    Exam Pass Rate: 75
    -
    Reference: 0064-0000-16-222-H01-P

Faculty and Disclosures

Additional Contributors

null

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error